Eli Lilly, Boehringer Ingelheim's Jardiance turns up heat on AstraZeneca's Farxiga with broad EU heart failure approval

Eli Lilly and Boehringer Ingelheim’s diabetes blockbuster Jardiance recently snagged a heart failure label expansion in the U.S. Now, the drug is widening its cardiovascular reach into Europe, with a nod that could help the med play catch-up with AstraZeneca’s SGLT2 rival Farxiga.